Discover the top movers in Wednesday's pre-market session. The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Tuesday's pre-market session: top gainers and losers Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
What's going on in today's session Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Which stocks are experiencing notable movement on Monday? Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
These stocks are gapping in today's session There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
These stocks are moving in today's pre-market session Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Unusual volume stocks in Friday's session Discover the stocks with unexpected trading volume in today's session on the US markets.
Traders are paying attention to the gapping stocks in Friday's session. Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.
Top movers in Friday's pre-market session The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
What's going on in today's after hours session After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
In today's session, these stocks are experiencing unusual volume. Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session.
EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors Indaptus advanced its Decoy20 trial to test a combination with tislelizumab, aiming to enhance checkpoint inhibitor effectiveness in cancer treatment.
INDP Stock Earnings: Indaptus Therapeutics Beats EPS for Q2 2024 INDP stock results show that Indaptus Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
